A Preview Of Harrow's Earnings

Harrow (NASDAQ:HROW) is preparing to release its quarterly earnings on Monday, 2026-03-02. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Harrow to report an earnings per share (EPS) of $0.42.

The announcement from Harrow is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

Earnings History Snapshot

During the last quarter, the company reported an EPS beat by $0.11, leading to a 13.47% increase in the share price on the subsequent day.

Here's a look at Harrow's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	0.22	0.04	0.01	0.13
EPS Actual	0.33	0.24	-0.38	0.40
Price Change %	13.47	3.23	3.43	-5.96

eps graph

Performance of Harrow Shares

Shares of Harrow were trading at $53.99 as of February 26. Over the last 52-week period, shares are up 108.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Delving into Harrow's Background

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Harrow: Delving into Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Positive Revenue Trend: Examining Harrow's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.44% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Harrow's net margin excels beyond industry benchmarks, reaching 1.42%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.11%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Harrow's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.29% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.36, caution is advised due to increased financial risk.

To track all earnings releases for Harrow visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.